GlaxoSmithKline PLC (GSK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

GlaxoSmithKline PLC (GSK)

52.50

+0.61 (1.18%)

as of Jun 26, 2026, 8:00:00 pm Market Open.

83 watching

Investor Insights

Jun 26, 2026, 12:00 am

This summary was created by AI, based on 5 opinions in the last 12 months.

GlaxoSmithKline PLC (GSK) is demonstrating promising progress, as indicated by various top picks and substantial gains from previous recommendations. Michael O'Reilly, the Stockchase Research Editor, has suggested a disciplined approach with trailing stop recommendations that reflect the stock's upward trajectory. The reviews highlight a robust performance, particularly with an 80% increase from the initial pick, and advocate for adjusting stop levels to secure profits. Despite challenges in their vaccine division tied to broader market sentiment, GSK's ongoing trials could enhance their competitive edge in pharmaceuticals. Overall, experts express optimism regarding GSK's potential to navigate current market pressures successfully.

Consensus

Positive

Valuation

Fair Value

Similar

PFE

TOP PICK

Growth in revenue, earnings, cash flow and earnings per share shall not better than its peers. Stable of products is very, very good. Good dividend.

BUY

Likes the pharmaceutical sector. The whole pharmaceutical area is cheap. Has a good pipeline. Pays a good dividend. Cheap. Well run.

DON'T BUY

A lot of trouble with these companies is having access to new products. They are so large now they have to continually feed the pipeline at an accelerated rate by acquiring at higher prices.

PAST TOP PICK

(A Top Pick May 8/06. Down 4%.) Pays at 3.5% dividend.

TOP PICK

Have increased the products in their pipeline. AA credit. 3.5% yield. Good long-term outlook.

BUY

5% dividend. The European pharmaceuticals have been in better shape generally than their US counterparts, so they are probably a better value story than this one. They’re looking to acquire to help their drug pipeline.

BUY

The 2nd largest pharmaceutical supplier globally. They also have good health care as well. Have an excellent pipeline, good dividend and good management.

BUY

Buying it now for 2005/2006 because, looking down the road, they are getting a 3.5/4% yield. A great way to play India.

TOP PICK

Dividend yield of more than 5%. They have a major portion of the pharmaceutical industry in India. May have to be patient.

WEAK BUY

They don't have a great pipeline. Have good profit margins on some vaccines and AIDS medications. The price is decent.

BUY

Likes, but prefers Johnson & Johnson.

BUY

Will take a few years for their products to come through, but you are getting a free cash flow yield of about 12%.

BUY

Prefers over US pharmaceuticals. Better situated globally.

TOP PICK

Good value. Yield of 2.3%. Good pipeline of products. Good R & D budget.

BUY

Has a new drug, competing with Prozac. Also into biotechs, making good diversification.

Showing 91 to 105 of 109 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Kevin Simpson

Capital Wealth Planning

Bryn Talkington

Requisite Capital Management

Andrey Omelchak

LionGuard Capital Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

GlaxoSmithKline PLC (GSK)